{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:00:03Z","timestamp":1787007603823,"version":"build-2736575974"},"reference-count":98,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2023,2,1]]},"DOI":"10.1080\/17512433.2023.2174523","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:16:11Z","timestamp":1674890171000},"page":"133-148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"first","affiliation":[{"name":"Servicio de Farmacia \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe Av. Valencia, Spain"},{"name":"Grupo de Investigaci\u00f3n en Hematolog\u00eda y Hemoterapia, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe Av. Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5836","authenticated-orcid":false,"given":"Octavio","family":"Ballesta-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia \u00c1rea del Medicamento, Hospital Universitari i Polit\u00e8cnic La Fe Av. Valencia, Spain"},{"name":"Grupo de Investigaci\u00f3n en Hematolog\u00eda y Hemoterapia, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Hematolog\u00eda y Hemoterapia, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Valencia, Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitari i Polit\u00e8cnic La Fe. Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Hematolog\u00eda y Hemoterapia, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Valencia, Spain"},{"name":"Servicio de Hematolog\u00eda y Hemoterapia Hospital Universitari i Polit\u00e8cnic La Fe. Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.020"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04186-0"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.211615"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01148-x"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09085.x"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1044"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154247"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.811"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.072744"},{"key":"cit0012","author":"CENTER FOR DRUG EVALUATION AND RESEARCH","year":"2017","journal-title":"Food Drug Adm"},{"key":"cit0013","unstructured":"Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - midostaurin (rydapt) EMEA\/H\/C\/004095\/0000. 2017;44. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rydapt-epar-public-assessment-report_en.pdf."},{"key":"cit0014","unstructured":"U.S. Food and Drug Administration (FDA). Novartis pharmaceuticals corporation (2017) rydapt (midostaurin): US prescribing information. 2017; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.01.001"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13088"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2287-6"},{"key":"cit0018","author":"CENTER FOR DRUG EVALUATION AND RESEARCH","year":"2018","journal-title":"Food Drug Adm"},{"key":"cit0019","first-page":"3814","volume":"130","author":"Ouatas T","year":"2017","journal-title":"Blood"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037853"},{"key":"cit0021","first-page":"33","volume-title":"Oncology (Williston Park)","author":"Schlafer D","year":"2019"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218764257"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.449.449"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869453"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1177\/1715163516641136"},{"key":"cit0027","volume-title":"Bristol-myers squibb pharma","author":"European Medicines Agency (EMA)","year":"2013"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1316"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.017"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1805109"},{"key":"cit0031","unstructured":"U.S. Food and Drug Administration (FDA). Astellas pharma (2018) xospata (gilteritinib): US prescribing information. 2018; Available from: https:\/\/www.accessdata.fda.gov\/%0Adrugsatfda_docs\/label\/2018\/211349s000lbl.pdf."},{"key":"cit0032","first-page":"386","volume-title":"Haematol Conf 22th Congr Eur Hematol Assoc Spain","volume":"102","author":"Levis M","year":"2017"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145379"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0976"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14022"},{"key":"cit0037","unstructured":"Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - quizartinib (vanflyta) EMEA\/H\/C\/004468\/0000. 2019; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vanflyta-epar-refusal-public-assessment-report_en.pdf."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21078"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071266"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03915-1"},{"key":"cit0041","first-page":"NDA 212166","author":"U.S. Food and Drug Administration (FDA)","year":"2019","journal-title":"FDA Advis Comm Brief Doc"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8783"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-821629"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30150-0"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.263392"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04204-y"},{"key":"cit0047","unstructured":"European Medicines Agency (EMA). Bayer Pharmaceutical Division (2020) Nexavar (sorafenib): EU prescribing information. 2020; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexavar-epar-product-information_en.pdf."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1125"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.powtec.2015.04.044"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.08.007"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0048"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.004"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9514-3"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.06.063"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0280"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12458"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.506873"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0966"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.05.009"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.87"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001375"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2187-9"},{"key":"cit0064","unstructured":"Comitte for Medicinal Products from Human Use (CHMP). SCIENTIFIC DISCUSSION - sorafenib (nexavar) EMEA\/H\/C\/690\/II\/05. 2007; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/nexavar-h-c-690-ii-05-epar-scientific-discussion-variation_en.pdf."},{"key":"cit0065","unstructured":"Comitte for Medicinal Products from Human Use (CHMP). European public assessment resport (EPAR) - sorafenib (nexavar) EMEA\/H\/C\/000690\/II\/0035. 2014; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/nexavar-h-c-690-ii-35-epar-assessment-report-variation_en.pdf."},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0036"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2020.10.001"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080436"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0068-6"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000611"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0639-9"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0328-7"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.82"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1372-3"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25198"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4888"},{"key":"cit0077","unstructured":"Comitte for Medicinal Products from Human Use (CHMP). European Public Assessment Resport (EPAR) - ponatinib (iclusig) EMEA\/H\/C\/002695\/0000. 2013;"},{"key":"cit0078","volume-title":"Incyte biosciences distribution B.V","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3240-x"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12082"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.35"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23010119"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0302"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3002"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.07.062"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0225-y"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.109"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.182"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2160-7"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513044"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3695.3695"},{"key":"cit0093","unstructured":"NHS. Crenolanib for advanced or metastatic gastrointestinal stromal tumours (GISTs) with the D842V mutation in the PDGFRA gene. UK: National System of Health. 2018. p. 1\u201311."},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0205-y"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03744-5"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.06.011"},{"issue":"776","key":"cit0098","first-page":"e1","volume":"27","author":"Greco R","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2023.2174523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:40:59Z","timestamp":1676364059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2023.2174523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"alternative-id":["10.1080\/17512433.2023.2174523"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2023.2174523","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}